Targeting glucose metabolism with 2-deoxy-D-glucose for improving cancer therapy

Future Oncology

Volumn 5, Issue 5, 2009, Pages 581-585

  Dwarakarnath, B S ^a   Jain, Viney ^b  

^a INSTITUTE OF NUCLEAR MEDICINE AND ALLIED SCIENCES   (India)

^b Eco Development Foundation   (India)

Author keywords

[No Author keywords available]

Indexed keywords

DEOXYGLUCOSE; DIAZEPAM; ANTINEOPLASTIC AGENT; GLUCOSE;

CANCER SURVIVAL; CANCER THERAPY; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DIAPHORESIS; DRUG EFFICACY; DRUG HALF LIFE; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EDITORIAL; GENE EXPRESSION; GLIOBLASTOMA; GLUCOSE METABOLISM; GLUCOSE TRANSPORT; GLYCOLYSIS; HUMAN; LEUKEMIA; MEDITATION; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROSTATE TUMOR; PROTEIN PHOSPHORYLATION; RADIOIMMUNOTHERAPY; RADIOSENSITIVITY; SIDE EFFECT; THYROID CARCINOMA; ANIMAL; METABOLISM; NEOPLASM;

ANIMALS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; DEOXYGLUCOSE; GLUCOSE; HUMANS; NEOPLASMS;

EID: 69849087571     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.09.44     Document Type: Editorial

References (45)

1. Warburg O: The metabolism of tumors. Constable and Co, London, UK (1930).
2. Warburg O: On the origin of cancer cells. Science 123, 309-314 (1956).
3. Kim J, Dang Chi V: Cancer's molecular sweet tooth and the Warburg effect. Cancer Res. 66, 8927-8930 (2006).
4. Gillies RJ, Robey I, Gatenby RA: Causes and consequences of increased glucose metabolism of cancers. J. Nucl. Med. 49, S24-S42 (2008).
5. Gambhir SS: Molecular imaging of cancer with positron emission tomography. Nat. Rev. Cancer 2, 683-693 (2002).
6. Cao W, Fang F, Gibbs S et al.: Glucose uptake inhibitor sensitizes cancer cells to daunorubicin and overcomes drug resistance in hypoxia. Cancer Chemother. Pharmacol. 59, 495-505 (2007).
7. Xu RH, Pelicano H, Zhou Y et al.: Inhibition of glycolysis in cancer cells: a novel strategy to overcome drug resistance associated with mitochondrial respiratory defect and hypoxia. Cancer Res. 65, 613-621 (2005).
8. Di Cosimo S, Ferretti G, Papaldo P et al.: Lonidamine: Efficacy and safety in clinical trials for the treatment of solid tumors. Drugs Today 39, 157-173 (2003).
9. Spoden GA, Mazurek S, Morandell D et al.: Isotype-specific inhibitors of the glycolytic key regulator pyruvate kinase subtype M2 moderately decelerate tumor cell proliferation. Int. J. Cancer 123, 312-321 (2008).
10. Woodward GE, Cramer FB: 2-deoxy-D-glucose as an inhibitor of anaerobic glycolysis in tumor tissues. J. Franklin. Inst. 254, 259-260 (1952).
11. Brown J: Effects of 2-deoxyglucose on carbohydrate metabolism: review of the literature and studies in the rat. Metabolism 11, 1098-1112 (1962).
12. McComb RB, Yushok WD: Metabolism of ascites tumor cells. IV. Enzymatic reactions involved in adenosinetriphosphate degradation induced by 2-deoxyglucose. Cancer Res. 24, 198-205 (1964).
13. Lin X, Zhang F, Bradbury CM et al.: 2-Deoxy-d-glucose-induced cytotoxicity and radiosensitization in tumor cells is mediated via disruptions in thiol metabolism. Cancer Res. 63, 3413-3417 (2003).
14. Kurtoglu M, Gao N, Shang J et al.: Under normoxia, 2-deoxy-d-glucose elicits cell death in select tumor types not by inhibition of glycolysis but by interfering with N-linked glycosylation. Mol. Cancer Ther. 6, 3049-3058 (2007).
15. Heminger K, Jain V, Kadakia M, Dwarakanath B, Berberich SJ: Altered gene expression induced by ionizing radiation and glycolytic inhibitor 2-deoxy-glucose in a human glioma cell line: implications for radiosensitization. Cancer Biol. Ther. 5, 815-823 (2006).
16. Bell SE, Quinn DM, Kellett GL, Warr JR: 2-deoxy-d-glucose preferentially kills multidrug-resistant human KB carcinoma cell lines by apoptosis Br. J. Cancer 78, 1464-1470 (1998).
17. Dwarakanath BS, Adhikari JS, Khaitan D et al.: Growth inhibition and induction of apoptosis by 2-deoxy-d-glucose in human squamous carcinoma cell lines. Biomedicine 24, 36-47 (2005).
18. Laszlo J, Humphrey SR, Glodin A: Effects of glucose analogues (2-deoxy-d-glucose, 2-deoxy-D-galactose) on experimental tumors. J. Natl Cancer Inst. 24, 267-271 (1960).
19. Hunter AJ, Blekkenhorst GH: The effects of 2-deoxyglucose and amino-oxyacetic acid on the radiation response of mammalian cells in vitro. Int. J. Radiat. Biol. 73, 311-324 (1998).
20. Landau BR, Laszlo J, Stengle J et al.: Certain metabolic and pharmacologic effects in cancer patients given infusions of 2-deoxy-D-glucose. J. Nat. Cancer Inst. 21, 485-494 (1958).
21. Diaola RS, Dvorzhinski D, Thalasia A et al.: Therapeutic starvation and autophagy in prostate cancer: a new paradigm for targeting metabolism in cancer therapy. Prostate 68, 1743-1752 (2008).
22. Vijayaraghavan R, Kumar D, Dube SN et al.: Acute toxicity and cardio-respiratory effects of 2-deoxy-D-glucose: a promising radiosensitizer. Biomed. Environm. Sci. 19, 96-103 (2006).
23. Jain V, Pohlit W, Purohit SC: Influence of energy metabolism on the repair of X-ray damage in living cells. III. Effects of 2-deoxy-D-glucose on liquid holding reactivation in yeast. Biophysik. 10, 137-142 (1973).
24. Jain V: Modifications of radiation responses by 2-deoxy-d-glucose in normal and cancer cells. Ind. J. Nucl. Med. 11, 8-17 (1996).
25. Dwarakanath BS, Jain VK: Energy linked modification of the radiation response in a human cerebral glioma derived cell line. Int. J. Radiat. Oncol. Biol. Phys. 17, 1033-1040 (1989).
26. Dwarakanath BS, Zolzer F, Chandna S et al.: Heterogeneity in 2-deoxy-D-glucose induced modifications in energetic and radiation responses of human tumor cell lines. Int. J. Radiat. Oncol. Biol. Phys. 51, 1151-1161 (2001).
27. Jain VK, Kalia VK, Gopinath PM, Naqvi S, Kucheria K: Optimization of cancer therapy, part III. Effects of combinig 2-deoxy-D-glucose treatment with γ irradiation on normal mice. Ind. J. Exp. Biol. 17, 1320-1325 (1979).
28. Dwarakanath BS, Jain VK: Modification of the radiation induced damage by 2-deoxy-D-glucose in organ cultures of human cerebral gliomas. Int. J. Radiat. Oncol. Biol. Phys. 13, 741-746 (1987).
29. Juling-Pohlit L, Pohlit W, Blattmann H: Repair inhibition in tumors irradiated with fast protons and negative pions. Strahlenther. Onkol. 166, 6-9 (1990).
30. Dwarakanath BS, Singh S, Jain V: Optimization of tumour radiotherapy: Part V - radiosensitization by 2-deoxy-D-glucose and DNA ligand Hoechest-33342 in a murine tumour. Ind. J. Exp. Biol. 37, 865-870 (1999).
31. Mohanti BK, Rath GK, Anantha N et al.: Improving cancer radiotherapy with 2-deoxy-D-glucose: Phase I/II clinical trials on human cerebral gliomas. Int. J. Radiat. Oncol. Biol. Phys. 35, 103-111 (1996).
32. Singh D, Banerji AK, Dwarakanath BS et al.: Optimizing cancer radiotherapy with 2-deoxy-D-glucose: dose escalation studies in patients with glioblastoma multiforme. Strahlentherapie 181, 507-514 (2005).
33. Venkataramana NK, Prasanna KV, Vishwanath PN et al.: Enhanced radiation effect on the tumor with protection of normal brain during a combinational therapy of 2-deoxy-D-glucose and hypo fractionated radiotherapy in malignant gliomas. Presented at: International Symposium on Application of 2-Deoxy-D-Glucose in the Management of Cancer. INMAS, Delhi, India, November 8-10, 2006.
34. Shrivastava V, Mishra AK, Dwarakanath BS, Ravindranath T: Enhancement of radionuclide induced cytotoxicity by 2-DG in human tumor cell lines. J. Cancer Res. Ther. 2, 57-64 (2006).
35. Aft RL, Lewis JS, Zhang F, Kim J, Welch MJ: Enhancing targeted radiotherapy by copper (II)diacetyl-bis(N4methylthiosemicarbazone) using 2-deoxy-D-glucose. Cancer Res. 63, 5496-5504 (2003).
36. Jason L, Dearling J, Qureshi U et al.: Combining radioimmunotherapy with antihypoxia therapy 2-deoxy-D-glucose results in reduction of therapeutic efficacy. Clin. Cancer Res. 13, 1903-1910 (2007).
37. Dwarakanath BS, Khaitan D, Ravindranath T: 2-deoxy-D-glucose enhance the cytotoxic effects of topoisomerase inhibitors in human tumor cell lines. Cancer Biol. Ther. 3, 34-43 (2004).
38. Simons AL, Ahmad IM, Mattson DM, Dornfeld KJ, Spitz DR: 2-deoxy-D-glucose combined with cisplatin enhances cytotoxicity via metabolic oxidative stress in human head and neck cancer cells. Cancer Res. 67, 3364-3370 (2007).
39. Maschek G, Savaraj N, Priebe W et al.: 2-deoxy-D-glucose increases the efficacy of adriamycin and paclitaxel in human osteosarcoma and non-small cell lung cancers in vivo. Cancer Res. 64, 31-34 (2004).
40. Gupta S, Mathur R, Dwarakanath BS: Modi?cations of etoposide induced toxicity by 2-deoxy-D-glucose in Ehrlich ascites tumor bearing mice. Cancer Biol. Ther. 4, 87-94 (2005).
41. Raez LE, Rosenblatt J, Schlesselman J et al.: Combining glycolytic inhibitors with chemotherapy: Phase I trial of 2-deoxyglucose and docetaxel in patients with solid tumors. Presented at: American Society of Clinical Oncology Annual Meeting, Orlando, FL, USA, May 13-17 (2005).
42. Marsh J, Mukherjee P, Seyfried TN: Drug/diet synergy for managing malignant astrocytoma in mice: 2-deoxy-D-glucose and the restricted ketogenic diet. Nutr. Metab. 5, 33-37 (2008).
43. Varshney R, Dwarakanath BS, Jain V: Radiosensitization by 6-aminonicotinamide and 2-deoxy-D-glucose in human cancer cells. Int. J. Radiat. Biol. 81, 397-408 (2005).
44. Varshney R, Gupta S, Dwarakanath BS: Radiosensitization of murine Ehrlich Ascites tumor by a combination of 2-deoxy-D-glucose and 6 amino nicotinamide. Tech. Cancer Res. Treat. 3, 659-663 (2004).
45. Dwarakanath BS, Adhikari JS, Jain V: Hematoporphyrin derivatives potentiate the radiosensitizing effects of 2-DG in cancer cells. Int. J. Radiat. Oncol. Biol. Phys. 43, 1125-1133 (1999).